BetterLife Pharma (OTCB:BETRD) CEO Discusses Using Interferons to Defeat ‘Truly Evil Virus’
July 06, 2020 07:30 ET
|
BetterLife Pharma
New York City, July 06, 2020 (GLOBE NEWSWIRE) -- The CEO of BetterLife Pharma (OTCQB:BETRD) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, recently...
Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding
September 23, 2019 03:00 ET
|
Biogen Inc.
Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before...
New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
September 12, 2019 05:00 ET
|
Biogen Inc.
Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognitionAn analysis of data...
The Biosimilars Market will hit $69 billion by 2025: Global Market Insights, Inc.
May 22, 2019 05:30 ET
|
Global Market Insights, Inc
Selbyville, Delaware, May 22, 2019 (GLOBE NEWSWIRE) -- Recombinant glycosylated proteins segment of biosimilars market is estimated to grow at around 28.7% over the estimation period. Increase in...
Hemispherx to Present at the Marcum Microcap Conference in New York
May 20, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) will present at the Marcum Microcap Conference being held at the Grand Hyatt Hotel in New York City on Wednesday, May...
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus
September 08, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that the Company and USAMRIID scientists have agreed to test...
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
July 22, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print])...
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina
March 04, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y...